Nebivolol Stada

Nebivolol, the active ingredient in Nebivolol Stada, is a beta blocker presented as a tablet for oral use. It selectively blocks β1‑adrenergic receptors and provides nitric‑oxide‑mediated vasodilation, helping to lower elevated blood pressure in adult patients with hypertension. It is indicated for the management of primary hypertension and is approved for use across the European Union.

GNH USA supplies Nebivolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Nebivolol is a selective β1‑adrenergic blocker used in the management of hypertension.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary high blood pressure. - Isolated systolic hypertension: lowers elevated systolic pressure, particularly in older adults. - Hypertension with cardiovascular risk: contributes to overall risk reduction by improving vascular tone.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: reduced energy or feeling unusually tired. - Nausea: upset stomach with urge to vomit. - Bradycardia: slower than normal heart rate. - Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: sudden drop in blood pressure causing faintness. - Heart block: impairment of electrical conduction in the heart. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver injury: abnormal liver function tests or jaundice. - Acute heart failure exacerbation: worsening of cardiac function.

Nebivolol should be used with clinical monitoring and appropriate patient assessment. - Blood pressure monitoring: regularly check to ensure therapeutic targets are met. - Heart rate assessment: observe for excessive slowing of pulse. - Asthma or COPD caution: use carefully in patients with reactive airway disease. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Renal impairment: adjust dose if significant kidney dysfunction is present. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol may interact with other medicines; review patient medication lists.

Major Interactions (Avoid): - Other beta‑blockers: additive cardiac depression. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): risk of severe bradycardia. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increased nebivolol plasma levels.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect. - ACE inhibitors or ARBs: potential for additive blood pressure lowering. - NSAIDs: may blunt antihypertensive response. - Digoxin: monitor for bradycardia. - Antidiabetic agents: watch for hypoglycemia due to masking of symptoms.